Amgen Sees Strong Q4 Growth Even Without Horizon Contribution
Gains Driven By Volume For Many Products
The company increased its full-year guidance in anticipation of Horizon’s Q4 contribution and sales for the quarter jumped 20%, but even excluding those drugs product sales were up 5%.
